The ASCO Post

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC

The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC who had not received prior treatment for advanced disease, according to final overall survival analyses from the phase III FLAURA2 trial. These results were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and published in The New England Journal of Medicine.

Muscle-Invasive Bladder Cancer: IMvigor011 Trial Investigates ctDNA-Guided Adjuvant PD-L1 Inhibition

“By selecting patients based on ctDNA, we see a benefit not only for disease-free survival but also for overall survival with atezolizumab. This is the first time that an adjuvant immunotherapy trial has shown a benefit for survival in selected patients based on ctDNA testing.”

Significant Overall Survival Benefit With Enzalutamide Plus Leuprolide for Biochemically Recurrent Prostate Cancer

Enzalutamide in combination with leuprolide may improve overall survival outcomes over leuprolide or enzalutamide monotherapy in patients with biochemically recurrent prostate cancer, according to the final overall survival analysis of the phase III EMBARK trial.

Expanding Our Impact in Cervical Cancer Treatment: Novel Immunotherapies, Radiation Innovations, and Consideration of Rare Histologies

Visit the Gynecologic Cancer Resource Center for the latest news and research. Learn more.

Adjuvant Pembrolizumab in Merkel Cell Carcinoma

The randomized phase III STAMP trial (EA6174) is the largest clinical study to date evaluating immunotherapy vs observation as adjuvant therapy for Merkel cell carcinoma following surgical removal of the tumor.

Reversible TKI in HER2-Mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant NSCLC, according to data from the phase I/II SOHO-01 clinical trial; over 70% of the patients studied saw their tumors shrink or disappear.

ESMO Publishes Guidance on Large Language Model Use for Oncology Practice

The society has released its first set of recommendations for the use of AI large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP).